European Pharmaceutical Review

FEBRUARY 14, 2023

A key benefit of mRNA therapeutics is that manufacturing time is fast compared to antibodies or protein-based drugs. Sarah Bundra, Pharmaceutical Analyst at GlobalData also warned about patient safety: “introducing mRNA carries the risk of activating the immune system.”

Food and Drug Administration 105

Food and Drug Administration Medicine Safety Consulting 105

Pharmaceutical Technology

AUGUST 16, 2022

In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. months compared with patients treated with standard-of-care chemotherapy.

Food and Drug Administration 59

Food and Drug Administration Sales Patients Food 59

European Pharmaceutical Review

MAY 2, 2023

We believe that this acquisition will enable us to deliver greater value to patients with ocular diseases at high risk of blindness,” stated Naoki Okamura, President and CEO of Astellas. billion in 2028, according to GlobalData’s Pharma Intelligence Center. Avacincaptad pegol is forecasted to achieve sales of $1.09

Food and Drug Administration 52

Food and Drug Administration Pharma FDA Sales 52

Medico Reach

OCTOBER 17, 2022

million by 2028. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. The device replaces a connecting bone in the ankle joint and can be customized according to patient preference.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

Pharmaceutical Technology

SEPTEMBER 2, 2022

This is a result of intensive research efforts that have produced regimens that have prolonged patient survival, most of which are a combination of a proteasome inhibitor + an immunomodulatory drug (ie. billion global sales expected by 2028, followed by Tecvayli with $2.6bn, which would mark a huge win for J&J in the MM space.

Food and Drug Administration 59

Food and Drug Administration FDA Sales Marketing 59

Pharmaceutical Technology

MARCH 30, 2023

On the same day, researchers presented new interim data from the Phase III RUBY trial of GSK’s PD-1 antibody Jemperli (dostarlimab) in patients with primary advanced or recurrent endometrial cancer. As per GlobalData’s consensus forecasts, the drug is estimated to yield global sales of $34.79 billion in 2028.

Food and Drug Administration 52

Food and Drug Administration FDA Sales Food 52

pharmaphorum

SEPTEMBER 13, 2022

Over the past two centuries, researchers have identified more than 100 different types of blood cancer, while most patients may be familiar with the big three (leukaemia, lymphoma, and melanoma). In 39-year-old patient Sarah Newbury, Solly observed the appearance of fatigue and bone pain resulting from multiple fractures.

Food and Drug Administration 98

Food and Drug Administration Patients Engineering Physicians 98